(a)There is established a chronic kidney disease advisory committee. The advisory committee shall:
(1)Work directly with policymakers, public health organizations and educational institutions to:
(A)Increase awareness of chronic kidney disease in this state; and (B) Develop health education programs that:
(i)Are intended to reduce the burden of kidney disease throughout this state;
(ii)Include an ongoing health and wellness campaign that is based on relevant research;
(iii)Promote preventive screenings; and (iv) Are promoted through social media and public relations campaigns;
(2)Examine chronic kidney disease, kidney transplantation, including, but not limited to, kidney transplantation as a preferred treatment for chronic kidney disease, living and deceased kidney donation and rac
Free access — add to your briefcase to read the full text and ask questions with AI
(a) There is established a chronic kidney disease advisory committee. The advisory committee shall: (1) Work directly with policymakers, public health organizations and educational institutions to: (A) Increase awareness of chronic kidney disease in this state; and (B) Develop health education programs that: (i) Are intended to reduce the burden of kidney disease throughout this state; (ii) Include an ongoing health and wellness campaign that is based on relevant research; (iii) Promote preventive screenings; and (iv) Are promoted through social media and public relations campaigns; (2) Examine chronic kidney disease, kidney transplantation, including, but not limited to, kidney transplantation as a preferred treatment for chronic kidney disease, living and deceased kidney donation and racial disparities in the rates of individuals afflicted with chronic kidney disease; (3) Examine methods to reduce the occurrence of chronic kidney disease by controlling the most common risk factors, diabetes and hypertension, through early detection and preventive efforts at the community level and disease management efforts in the primary care setting; (4) Identify the barriers to the adoption of best practices and the policies available to address such barriers; (5) Develop an equitable, sustainable, cost-effective plan to raise awareness about the importance of early detection, screening, diagnosis and treatment of chronic kidney disease and prevention; and (6) Examine the potential for an opt-out organ or kidney donor registry. (b) The advisory committee shall consist of the following members: (1) One appointed by the speaker of the House of Representatives, who shall represent the renal provider community; (2) One appointed by the president pro tempore of the Senate, who shall represent a medical center with a kidney-related program; (3) One appointed by the majority leader of the House of Representatives; (4) One appointed by the majority leader of the Senate; (5) One appointed by the minority leader of the House of Representatives; (6) One appointed by the minority leader of the Senate; (7) One appointed by the Governor; (8) The Commissioner of Public Health, or the commissioner's designee; (9) One appointed by the chief executive officer of the National Kidney Foundation; (10) One appointed by the chief executive officer of the American Kidney Fund; and (11) At least three additional members appointed by the chairpersons of the joint standing committee of the General Assembly having cognizance of matters relating to public health, one of whom shall represent the kidney physician community, one of whom shall represent a nonprofit organ procurement organization, one of whom shall represent the kidney patient community in this state and such other members that such chairpersons, in their discretion, agree are necessary to represent public health clinics, community health centers, minority health organizations and health insurers. (c) Any member of the advisory committee appointed under subdivision (1), (2), (3), (4), (5), (6) or (11) of subsection (b) of this section may be a member of the General Assembly. (d) All initial appointments to the advisory committee shall be made not later than thirty days after May 23, 2022. Any vacancy shall be filled by the appointing authority. (e) The speaker of the House of Representatives and the president pro tempore of the Senate shall select the chairpersons of the advisory committee from among the members of the advisory committee. Such chairpersons shall schedule the first meeting of the advisory committee, which shall be held not later than sixty days after May 23, 2022. Meetings of the advisory committee may, at the discretion of the chairpersons of the advisory committee, be conducted on a virtual platform. (f) The administrative staff of the advisory committee shall be selected by the Office of Legislative Management in consultation with the chairpersons of the advisory committee. (g) Not later than January 1, 2024, and annually thereafter, the advisory committee shall submit a report on its findings and recommendations to the joint standing committee of the General Assembly having cognizance of matters relating to public health in accordance with the provisions of section 11-4a .